Smiths Detection Announces Acquisition of Med Graphix Inc.
MGI has been a long-standing service partner and third-party depot supplier for Smiths Detection. This deal marks a significant milestone in a partnership that has spanned more than two decades. MGI has been a trusted supplier of component-level repair, refurbishment, harvesting, and decommissioning services for Smiths Detection equipment. Their technical expertise and extensive experience have played a vital role in service delivery, inventory optimization, and cost reduction for several key Smiths Detection customers.
Integration planning began in March 2025 and will continue through the end of the year to ensure a seamless transition for both customers and employees. Effective 1 August 2025, MGI will be a fully integrated part of the Smiths Detection family.
Jerome de Chassey, President of Smiths Detection, said: 'This acquisition reinforces our commitment to service excellence and operational resilience. Bringing MGI in-house allows us to leverage their expertise while strengthening our global service infrastructure. It's a natural evolution of our long-standing partnership.'
With this strategic investment, Smiths Detection further enhances its ability to deliver critical services and support to make the world a safer place.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its TAH System has been accepted into the U.S. Food and Drug Administration's (FDA) prestigious Total Product Life Cycle (TPLC) Advisory Program, also known as the TAP program. This milestone further solidifies BiVACOR's collaboration with the FDA following the TAH's earlier recognition this year as a Breakthrough Device. This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology. The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with urgency and magnitude of our mission. Share The TAP program is a transformative FDA initiative designed to accelerate the development and patient access to high-impact medical technologies. Entry into the program provides BiVACOR with proactive, strategic engagement with the FDA throughout the entire product life cycle, from development to commercialization, supporting more efficient, risk-informed decision-making. TAP participation is reserved for breakthrough-designated devices with the potential to significantly improve patient outcomes for serious or life-threatening conditions. 'Acceptance into the TAP program marks a major milestone not just for BiVACOR, but for the field of mechanical circulatory support as a whole,' said Daniel Timms, Founder and Chief Technology Officer of BiVACOR. 'The BiVACOR TAH has the potential to fundamentally redefine the standard of care for patients with end-stage heart failure. TAP access gives us a powerful framework for working hand-in-hand with the FDA to bring this technology to the patients who need it most.' The BiVACOR TAH is intended for use as a bridge to transplant in adults with severe, irreversible biventricular or univentricular heart failure, particularly for patients who cannot be treated with traditional left ventricular assist devices (LVADs). The system employs a magnetically levitated centrifugal pump, inspired by space and industrial technologies, which provides continuous, pulsatile, and physiologically responsive cardiac support. The FDA's acceptance letter to BiVACOR emphasized that the TAP program's inclusion reflects the agency's confidence in the technology's potential to transform clinical practice. As part of the program, BiVACOR will receive more regulatory guidance, earlier identification of scientific and evidentiary gaps, and greater coordination among stakeholders, including payers and patient advocacy groups. 'This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology,' said William Cohn, MD, BiVACOR Chief Medical Officer and renowned cardiac surgeon. 'The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with the urgency and magnitude of our mission to bring a durable, fully implantable artificial heart to patients with no other options.' The TAP program was established as part of the FDA's efforts to modernize device development oversight and ensure the U.S. remains at the forefront of medical innovation. The program currently operates as a pilot under the Center for Devices and Radiological Health (CDRH), with acceptance based on strict criteria outlined in the Federal Register (87 FR 61605). BiVACOR's participation in TAP follows several recent milestones for the company, including its first-in-human implant as a bridge to support a patient awaiting a cardiac transplant. The company is now progressing toward expanded clinical trials in the U.S. and internationally. For more information on the FDA's TAP program, visit: Participation in the FDA's Total Product Life Cycle Advisory Program (TAP) does not imply FDA approval, clearance, or authorization. Inclusion in the TAP Pilot does not guarantee future marketing authorization or a regulatory outcome. The BiVACOR TAH is currently used as an investigational device and is not approved for commercial use. About BiVACOR BiVACOR ® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at
Axios
26 minutes ago
- Axios
Online grocer Weee must pay Mass. workers misclassified as contractors
An online grocery delivery company must pay Massachusetts delivery drivers nearly $800,000, settling allegations that it misclassified the workers and denied them earned sick time. Why it matters: Massachusetts Attorney General Andrea Campbell continues to take companies using delivery drivers as independent contractors to task, long after the high-profile battles with ride app companies like Uber and Lyft over employee classification. Driving the news: A California-based Asian online supermarket called Weee agreed to an $865,000 settlement with Campbell's office over allegations that 164 workers were misclassified as independent contractors. The bulk of that money is restitution for the workers, who Campbell's office says weren't able to earn sick time or take advantage of other protections afforded to full-time employees. The remaining $80,000 covers fines the company agreed to pay, per the settlement agreement Campbell signed last Thursday. Weee did not immediately respond to an inquiry from Axios.
UPI
27 minutes ago
- UPI
Claire's files second bankruptcy petition in 7 years
Retailer Claire's filed for bankruptcy protection on Wednesday amid declining sales and rising costs due to inflation and the potential impact of tariffs on its mostly Chinese-made goods. File Photo by John Angelillo/UPI | License Photo Aug. 6 (UPI) -- Officials for retailer Claire's filed for bankruptcy protection on Wednesday as its operating costs rise while demand for its goods declines among its youthful customers. A combination of tariffs on the mostly Chinese-produced goods sold by Claire's and inflation has cooled demand among its mostly youthful customers, according to NPR. So has its distribution system of brick-and-mortar storefronts inside malls at a time when its traditionally youthful shoppers prefer buying goods online. Illinois-based Claire's has a $500 million loan due for payment next year, but its declining revenues and profits endanger its stores in the United States and Canada. "Increased competition, consumer spending trends and the ongoing shift away from brick-and-mortar retail, in combination with our current debt obligations and macroeconomic factors, necessitate this course of action for Claire's and its stakeholders," Claire's Chief Executive Officer Chris Cramer said in a prepared statement. Claire's counterpart in Canada likely will file for bankruptcy protection there, but the retailer's North American stores will remain open. "We remain in active discussions with potential strategic and financial partners and are committed to completing our review of strategic alternatives," Cramer said. Claire's filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for Delaware. The retailer is noted for its low-cost fashion accessories, jewelry and piercing services. In 2018, the company filed for bankruptcy protection. Elliott Management Corp. and Monarch Alternative Capital now control Claire's, which wiped out $1.9 billion in debt and kept its retail outlets open after securing a $575 million loan, according to CNBC. The retailer cited between $1 billion and $10 billion in assets and liabilities alike in Wednesday's bankruptcy filing. Tariffs on Chinese-made goods could affect Claire's supply chain, and increased competition from ear-piercing service providers is affecting Claire's business among its younger customers. "Competition has ... become sharper and more intense over recent years," GlobalData managing director Neil Saunders recently said. "Retailers like Lovisa [are] offering younger shoppers a more sophisticated assortment at value prices," Saunders said. "This is more attuned to what younger consumers want and has left Claire's looking somewhat out of step with modern demand," he added. Amazon and other online retailers also are negatively affecting Claire's business model, according to Saunders.
